Adrenocortical
carcinoma (ACC) is a rare and highly aggressive carcinoma. According to the US
National Library of Medicine, the overall 5-year mortality rate of 75 - 90% and
an average survival from the time of diagnosis of 14.5 months. The rising
incidence rate, a rise in the number of drugs in clinical trials for specific
chemotherapeutics, and the increase in risk-factors are anticipated to drive
the growth of the market during the assessment period. According to the
International Pediatric Adrenocortical Tumor Registry, the female-to-male ratio
for adrenocortical carcinoma is approximately 2.5-3:1. Inherited disorders such
as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney
complex are linked with increased incidences of adrenocortical carcinoma.
According to the survey by Endocrine Society, 2014, adrenocortical carcinoma
comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of
malignancies in BWS. However, differentiation of benign and malignant
tumor in the initial stages needs proper evaluation. The pathohistological
diagnosis also remains challenging. These factors coupled with the lack
of oncology experts may restrain the growth of the market during the forecast
period.
On
a regional basis, the adrenocortical carcinoma treatment market in the Americas
is anticipated to dominate the market during the forecast period. The market
growth in this region is owing to the advanced healthcare expenditure and
advancements in medical device technologies. Moreover, higher demand for
quality products and the availability of reimbursement policies are expected to
contribute to the market growth in this region.
Currently,
the global adrenocortical carcinoma treatment market is dominated by several
players. The prominent players in this market are involved in new product
launches, strategic partnerships to expand their product portfolio. For
instance, in April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase
2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2
fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR
translocations, amplification, and mutations. ARQ 087 is a potent FGFR
(Fibroblast Growth Factor Receptor) inhibitor. Also, in March 2018, the
University of Colorado Anschutz Medical Campus presented novel models to recognize
genetic targets and test promising treatments in adrenocortical carcinoma at
the ENDO Conference exploring a new therapeutic option.
Access
Report @ https://www.marketresearchfuture.com/reports/adrenocortical-carcinoma-treatment-market-6567
The global adrenocortical carcinoma treatment
market has been segmented into type, therapy, and end-user
No comments:
Post a Comment